Log In Get Started
Press Releases April 17, 2026 03:37 PM

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Announces Earlier Shareholder Update Call To Discuss Celularity Transaction

By Marcus Reed NXGL
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
NXGL

NEXGEL, Inc. has rescheduled its shareholder update conference call from April 23rd to April 21st, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. The company produces healthcare, beauty, and OTC hydrogel products and maintains strategic manufacturing partnerships.

Key Points

  • NEXGEL is advancing its shareholder call to discuss the Celularity transaction, indicating possible significant corporate developments.
  • NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications, with multiple proprietary brands.
  • The company maintains strategic contract manufacturing relationships with major consumer healthcare firms, highlighting its industry integration and manufacturing capabilities.

LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET.

Shareholder Update Call Details:
Date: April 21, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
[email protected]


Risks

  • Details regarding the Celularity transaction are limited, creating uncertainty around its potential benefits or challenges for NEXGEL.
  • Rescheduling the conference call might indicate urgency or pending issues, which could introduce investor apprehension.
  • Dependence on contract manufacturing relationships exposes the company to risks from third-party business changes or operational disruptions.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026